Epidemiology and predictors of a poor outcome in elderly patients with candidemia  by Guimarães, Thaís et al.
International Journal of Infectious Diseases 16 (2012) e442–e447Epidemiology and predictors of a poor outcome in elderly patients with
candidemia
Thaı´s Guimara˜es a,b,*, Ma´rcio Nucci c, Joa˜o S. Mendonc¸a b, Roberto Martinez d, Ligia R. Brito a,e, Nivia Silva b,
Maria Luiza Moretti f, Reinaldo Saloma˜o g, Arnaldo L. Colombo a
aUniversidade Federal de Sa˜o Paulo, Sa˜o Paulo, Brazil
bHospital do Servidor Pu´blico Estadual de Sa˜o Paulo, Sa˜o Paulo, Brazil
cUniversidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
dUniversidade de Sa˜o Paulo, Campus Ribeira˜o Preto, Ribeira˜o Preto, Brazil
eHospital Beneﬁceˆncia Portuguesa, Sa˜o Paulo, Brazil
fUniversidade Estadual de Campinas, Campinas, Brazil
g Casa de Sau´de Santa Marcelina, Sa˜o Paulo, Brazil
A R T I C L E I N F O
Article history:
Received 7 September 2011
Accepted 2 February 2012
Corresponding Editor: William Cameron,
Ottawa, Canada
Keywords:
Candidemia
Elderly
Epidemiology
Bloodstream infections
S U M M A R Y
Background: Candidemia affects patient populations from neonates to the elderly. Despite this, little
information is available about the epidemiology of candidemia in elderly patients.
Methods: We performed a retrospective analysis of 987 episodes of candidemia in adults (>14 years of
age) from the databases of three laboratory-based surveys of candidemia performed at 14 tertiary care
hospitals. Patients aged 60 years were considered elderly (group 1, n = 455, 46%) and were compared to
younger patients (group 2, n = 532, 54%) regarding demographics, underlying diseases, comorbidities,
exposure to medical procedures, species, treatment, and outcome.
Results: The median APACHE II score was signiﬁcantly higher in the elderly patients (19 vs. 15, p = 0.03).
Variables that were observed signiﬁcantly more frequently in elderly patients included admission to an
intensive care unit, diabetes mellitus, renal failure, cardiac disease, lung disease, receipt of antibiotics or
H2 blockers, insertion of a central venous catheter, mechanical ventilation, and candidemia due to
Candida tropicalis. The 30-day mortality of elderly patients was signiﬁcantly higher than that of younger
patients (70% vs. 45%, p < 0.001). Factors associated with higher mortality by multivariate analysis
included APACHE II score and being in group 1 (elderly). Factors associated with mortality in elderly
patients were lung disease and the receipt of mechanical ventilation.
Conclusions: Elderly patients account for a substantial proportion of patients with candidemia and have
a higher mortality compared to younger patients.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The incidence of candidemia in tertiary care hospitals worldwide
has increased substantially over recent decades.1 Candidemia
represents a signiﬁcant cause of morbidity and mortality, particu-
larly among critically ill patients. In addition, candidemia prolongs
hospital stays and increases the costs associated with patient
management.2,3 The epidemiology of candidemia has been studied
extensively worldwide, and data are available from a large series of
laboratory-based and population-based surveillance studies, as well
as studies focusing on speciﬁc patient populations such as neonates,
cancer, surgical, and intensive care unit (ICU) patients.4–8 Although
elderly patients represent a signiﬁcant proportion of patients with* Corresponding author. Av. dos Eucaliptos 155 Apto. 121 Zip Code: 04517-050
Sa˜o Paulo Brazil. Tel.: +55 11 5093 2218; fax: +55 11 5549 1565.
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1201-9712/$36.00 – see front matter  2012 International Society for Infectious Disea
doi:10.1016/j.ijid.2012.02.005candidemia (24–57% in a majority of published series), few
investigators have speciﬁcally addressed the epidemiological
aspects of candidemia in this population.9,10 Because bloodstream
infections in these patients have different clinical presentations and
outcomes when compared to those in younger individuals, we
hypothesized that candidemia in elderly patients would present
several peculiarities for patient care.11,12 To characterize these
putative peculiarities in elderly patients, we evaluated a database of
patient candidemia from three multicenter, prospective, laboratory-
based surveillance studies coordinated by our group, and compared
the clinical and epidemiological aspects of candidemia in older
versus younger patients.
2. Patients and methods
This was a retrospective analysis of a database of candidemia
generated by combining the databases from three prospective,ses. Published by Elsevier Ltd. All rights reserved.
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medical centers in Brazil between June 1994 and December
2004.13–15 The three studies enrolled solely tertiary care hospitals
with automated blood culture systems (BACTEC or BacT-ALERT),
providing medical care to adults and children in different medical
specialties. The case report form and the strategy for data
collection were the same across the three surveillance studies.
For each center, an investigator was speciﬁcally trained to
maintain daily contact with the hospital microbiology laboratory
and to collect clinical and epidemiological data for all incident
cases of candidemia. Investigators were equipped with a standard
case report form and a dictionary of terms that included all
deﬁnitions of underlying conditions and medical exposures
collected during the study. In addition, all Candida bloodstream
isolates were sent to a central laboratory for species identiﬁcation.
Isolates were identiﬁed according to their microscopic morphology
on corneal Tween 80 agar and by biochemical analysis using the ID
32C system (bioMe´rieux, Marcy l’Etoile, France).
The following variables were collected for each patient at the
time of enrollment: age, gender, date of admission, date of
candidemia, duration of hospitalization, APACHE II score (for
critically ill patients), medical ward, underlying medical condi-
tions, exposure to invasive medical procedures, use of antibiotics
or corticosteroids, management of candidemia (antifungal treat-
ment and catheter removal), and outcome. A case of candidemia
was deﬁned by the initial isolation of Candida spp from a blood
culture. Candidemia occurring >30 days after the initial isolation
was deﬁned as a new case. Patients were followed for 30 days after
the diagnosis of candidemia.
Neutropenia was deﬁned as an absolute neutrophil count of
<0.5  109/l. We considered as conditions associated with
candidemia those present 30 days before the date of the incident
candidemia. Underlying diseases were considered if the patient
presented any condition requiring active treatment in the previous
3 months. Cardiac disease was considered if the patient had
congestive heart failure, coronary arterial disease, hypertension, or
cardiac arrhythmias; pulmonary disease was considered if the
patient had chronic obstructive pulmonary disease, asthma,
bronchiectasis, granulomatous lung disease, or any restrictive
pulmonary disease; neurological disease was considered if the
patient had a stroke, or had Parkinson’s disease, any type of
dementia, or convulsions; and liver disease was considered if the
patient had chronic viral or drug hepatitis, any type of cirrhosis, or
biliary diseases that required surgery. Diabetes mellitus was
considered if the patient required speciﬁc medication to maintain
normal glucose levels. Renal failure was deﬁned as any docu-
mented serum creatinine value >1.5 g/dl.
Patients 60 years old were considered elderly (group 1) and
those <60 years old were considered younger (group 2). Patients
aged <14 years were excluded from the analysis. We compared
elderly patients (group 1) with younger patients (group 2)
regarding baseline characteristics, clinical manifestations, species
distribution, treatment, and outcome. Categorical data were
analyzed using Chi-square or Fisher’s exact tests, as appropriate,
and continuous variables were compared using the Wilcoxon test.
A p-value of <0.05 was considered statistically signiﬁcant.
Variables signiﬁcant at p < 0.1 by univariate analysis were
included in a multivariate model (backward and forward).
Statistical analyses were performed using SPSS version 15.0 (SPSS,
Inc., USA).
3. Results
Among the 987 patients >14 years of age, 455 (46%) were
elderly (group 1) and 532 (54%) were younger (group 2). Elderlypatients accounted for 29–69% of patients in the 14 participating
hospitals.
Table 1 shows the comparison of baseline characteristics
between the two groups. The median age of group 1 was 72 years
(range 60–99 years) and of group 2 was 41 years (range 14–59
years). Elderly patients were more likely to be in an ICU at the time
of diagnosis of candidemia and less likely to be in a medical or
hematology ward compared to younger patients. In addition, the
median duration of hospitalization before the onset of candidemia
was signiﬁcantly higher among elderly patients (24 vs. 19 days,
p < 0.001). Likewise, the presence of certain comorbidities, such as
diabetes, renal failure, cardiac disease, and lung disease were more
likely to be present in elderly patients. In contrast, liver disease was
more frequent among younger patients. Elderly patients were
sicker, as shown by the signiﬁcantly higher median APACHE II
score on the day of the incident candidemia (19 vs. 15, p = 0.03).
Other variables more frequently observed in elderly patients were
the receipt of antibiotics and H2 blockers, the presence of a central
venous catheter (CVC), and receipt of mechanical ventilation.
Neutropenia, organ transplantation, and the receipt of cancer
chemotherapy were more frequently observed in younger patients.
As shown in Table 2, non-albicans species accounted for 61% of
candidemias. Candida tropicalis (24%) and Candida parapsilosis
(21%) were the most frequent non-albicans species. Of note,
Candida glabrata accounted for only 7% of cases. Candidemia due to
C. tropicalis was more common among elderly patients (28% vs.
21%, p = 0.02), whereas C. parapsilosis was more frequent among
younger patients (24% vs. 18%, p = 0.02). We further explored the
association between elderly patients and C. tropicalis candidemia
by stratifying patients by cancer diagnosis. Among patients
without cancer, candidemia due to C. tropicalis was observed in
21% of younger and 24% of elderly patients (p = 0.23). In contrast,
among patients with cancer, C. tropicalis candidemia occurred in
23% of younger and 35% of elderly patients (p = 0.02).
Overall, 68% of patients received antifungal therapy – 70% of
younger patients and 66% of elderly patients (p = 0.12). The median
time from the diagnosis of candidemia to the initiation of
antifungal therapy was 3 days (range 10 to 39 days) and was
similar in the two groups (p = 0.46). Deoxycholate amphotericin B
was the most frequent agent used as primary therapy (394 of the
673 patients who received treatment, 59%), followed by ﬂucona-
zole (37%). Other treatments included a lipid formulation of
amphotericin B (three episodes), caspofungin (three episodes),
voriconazole (two episodes), and a blind drug in a randomized
clinical trial (20 episodes). Deoxycholate amphotericin B was more
likely to have been used in younger patients (239 of 374 younger
patients, 64%, vs. 155 of 299 elderly patients, 52%, p = 0.001),
whereas ﬂuconazole was more frequently used in elderly patients
(136 of 299, 45%, vs. 115 of 374, 31%, p < 0.001).
On day 30 after the diagnosis of candidemia, 57% of patients had
died – 71% of elderly patients and 45% of younger patients
(p < 0.001). As shown in Table 3, variables associated with higher
30-day mortality by univariate analysis included age group
(elderly), hospitalization in an ICU, certain underlying medical
conditions such as diabetes mellitus, renal failure, cardiac disease,
and lung disease, higher APACHE II score on the day of diagnosis of
candidemia, presence of a CVC, abdominal surgery, receipt of
mechanical ventilation, total parenteral nutrition, dialysis, and
corticosteroids, and candidemia due to Candida albicans, C.
tropicalis, and C. glabrata. Factors associated with better survival
at day 30 were neutropenia, receipt of cancer chemotherapy, and
candidemia due to C. parapsilosis.
By multivariate analysis, APACHE II score (odds ratio (OR) 1.074,
95% conﬁdence interval (95% CI) 1.022–1.129, p = 0.005) and being
in group 1 (elderly) (OR 2.16, 95% CI 1.14–4.10, p = 0.02) were
signiﬁcantly associated with 30-day mortality. However, because
Table 2
Species distribution of candidemic episodes in elderly (group 1) and younger (group 2) patients
Candida species All patients
(N = 987)
Group 1 (60 years)
(n = 455)
Group 2 (<60 years)
(n = 532)
p-Valuea
C. albicans 386 (39) 184 (40) 202 (38) 0.43
C. tropicalis 240 (24) 126 (28) 114 (21) 0.02
C. parapsilosis 209 (21) 82 (18) 127 (24) 0.02
C. glabrata 66 (7) 31 (7) 35 (7) 0.89
C. rugosa 29 (3) 11 (2) 18 (3) 0.37
C. krusei 18 (2) 8 (2) 10 (2) 0.42
C. guilliermondii 16 (2) 7 (1.5) 9 (2) 0.85
C. lusitaniae 10 (1) 2 (0.5) 8 (1.5) 0.12
Otherb 8 (1) 4 (1) 4 (1.5) 1.00
a p-Value for the comparison between the two groups.
b Other species included Candida famata (two cases in group 1 and four in group 2) and Candida sp (two cases in group 1).
Table 1
Baseline characteristics and coexisting exposures of elderly (group 1) and younger (group 2) patients with candidemia
Variable All patients
(N = 987)
Group 1 (60 years)
(n = 455)
Group 2 (<60 years)
(n = 532)
p-Valuea
Gender male/female, n 569/418 270/185 299/233 0.32
Ward, n (%)
ICU 374 (38) 202 (44) 172 (32) <0.001
Medical 298 (30) 122 (27) 176 (33) 0.03
Surgical 187 (19) 90 (20) 97 (18) 0.54
Emergency 61 (6) 29 (6) 32 (6) 0.81
Hematology 60 (6) 8 (2) 52 (10) <0.001
Gynecology 7 (1) 4 (1) 3 (1) 1.00
Duration (days) of hospitalization before
candidemia, median (range)
21 (0–611) 24 (0–324) 19 (0–611) <0.001
Underlying disease, n (%)b
Cancer 314 (32) 143 (31) 171 (32) 0.81
Hematological malignancy 167 (17) 18 (4) 149 (28) <0.001
Solid tumor 147 (15) 125 (27) 22 (4) <0.001
Diabetes mellitus 152 (15) 109 (24) 43 (8) <0.001
Neurological disease 143 (14) 60 (13) 83 (16) 0.28
Renal failure 161 (16) 89 (20) 72 (14) 0.01
Cardiac disease 119 (12) 83 (18) 36 (7) <0.001
Lung disease 80 (8) 49 (11) 31 (6) 0.005
Liver disease 54 (5) 15 (3) 39 (7) 0.005
Immunological disease 31 (3) 10 (2) 21 (4) 0.12
AIDS 36 (4) 2 (0.4) 34 (6) <0.001
APACHE II score, median (range)c 17 (2–42) 19 (5–42) 15 (2–39) 0.03
Coexisting exposures, n (%)b
Receipt of antibiotics 903 (92) 434 (95) 469 (88) <0.001
Central venous catheter 632 (64) 369 (81) 263 (49) <0.001
Receipt of H2 blockers 768 (78) 372 (82) 396 (74) 0.006
Surgery 418 (42) 191 (42) 227 (43) 0.83
Abdominal surgery 208 (21) 111 (24) 97 (18) 0.02
Mechanical ventilation 455 (46) 242 (53) 213 (40) <0.001
Receipt of corticosteroids 377 (38) 179 (39) 198 (37) 0.49
Receipt of total parenteral nutrition 190 (19) 83 (18) 107 (20) 0.46
Receipt of dialysis 169 (17) 79 (17) 90 (17) 0.85
Neutropenia 95 (10) 21 (5) 74 (14) <0.001
Organ transplantation 13 (1) 1 (0.2) 12 (2) 0.005
Receipt of cancer chemotherapy 102 (10) 20 (4) 82 (15) <0.001
ICU, intensive care unit; AIDS, acquired immunodeﬁciency syndrome; APACHE, Acute Physiology and Chronic Health Evaluation.
a p-Value for the comparison between the two groups.
b The sum exceeds 100% because patients may have had more than one underlying condition or coexisting exposure.
c Data available for only 220 patients (108 in group 1 and 112 in group 2).
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performed a second multivariate analysis excluding this variable in
order to analyze the whole patient population (987 episodes of
candidemia). As shown in Table 4, age group was an independent
variable associated with 30-day mortality (OR 3.38, 95% CI 2.34–
4.87). The other signiﬁcant variables were lung disease, candide-
mia due to C. glabrata, and the receipt of mechanical ventilation,
dialysis, and total parenteral nutrition. Among elderly patients,
factors associated with 30-day mortality were lung disease and the
receipt of mechanical ventilation. In contrast, variables signiﬁ-
cantly associated with 30-day mortality in younger patients werecandidemia due to C. glabrata, lung disease, receipt of mechanical
ventilation, parenteral nutrition, and dialysis, and neutropenia.
4. Discussion
Infections in elderly patients are currently a major public health
concern, gaining increasing relevance because of the expansion of
the elderly population worldwide.16 In addition, the population of
immunocompromised patients in this age group has increased,
with an expanded population of elderly patients undergoing organ
transplantation and receiving aggressive regimes of cancer
Table 3
Univariate analysis of factors associated with 30-day mortality among 987 adult patients with candidemia
Variable Died (n = 561) Survived (n = 426) p-Value
Age group elderly, n (%) 321 (57) 134 (31) <0.001
Gender male/female, n 325/236 244/182 0.84
Hospitalization in the intensive care unit, n (%) 262 (47) 112 (26) <0.001
Underlying disease, n (%)
Cancer 188 (34) 126 (30) 0.19
Diabetes mellitus 100 (18) 52 (12) 0.01
Neurological disease 79 (14) 64 (15) 0.68
Renal failure 105 (19) 56 (13) 0.02
Cardiac disease 81 (14) 38 (9) 0.008
Lung disease 70 (12) 10 (2) <0.001
Liver disease 35 (6) 19 (4) 0.22
APACHE II score, median (range)a 20.5 (7–42) 13 (2–34) <0.001
Coexisting exposures, n (%)
Central venous catheter 401 (71) 231 (54) <0.001
Surgery 242 (43) 176 (41) 0.57
Abdominal surgery 136 (24) 72 (17) 0.005
Mechanical ventilation 331 (59) 124 (29) <0.001
Receipt of corticosteroids 238 (42) 139 (33) 0.002
Receipt of total parenteral nutrition 128 (23) 62 (15) 0.001
Receipt of dialysis 119 (21) 50 (12) <0.001
Neutropenia 45 (8) 50 (12) 0.05
Organ transplantation 7 (1) 6 (1) 0.83
Receipt of cancer chemotherapy 46 (8) 56 (13) 0.01
Candida species
C. albicans 235 (42) 151 (35) 0.04
C. tropicalis 150 (27) 90 (21) 0.04
C. parapsilosis 84 (15) 125 (29) <0.001
C. glabrata 49 (9) 17 (4) 0.003
Treatment, n (%)
Deoxycholate amphotericin B 203 (36) 191 (45) 0.006
Fluconazole 131 (23) 120 (28) 0.08
Time (days) from diagnosis of candidemia to
treatment initiation, median (range)
2 (10 to 23) 3 (10 to 39) 0.04
a Data available for only 220 patients.
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diseases.17 Finally, elderly patients are hospitalized more fre-
quently and have a higher mortality rate, longer hospitalization,
and increased risk of disability when compared with younger
patients.18
Although underlying medical conditions typically associated
with candidemia are frequent in the elderly population, the
proportion of elderly patients in different studies of candidemia
has not been extensively reported. With different deﬁnitions of
‘elderly’ (>60 or >65 years of age), the proportion has ranged from
24% to 46% in the USA,10,19 41% to 57% in Europe,9,20 22% to 48% inTable 4
Multivariate analysis of factors associated with 30-day mortality among 987 adult pat
Variablea OR 
All patients
Lung disease 4.35 
Candidemia due to C. glabrata 3.58 
Age group elderly 3.38 
Receipt of mechanical ventilation 2.61 
Receipt of dialysis 2.18 
Receipt of total parenteral nutrition 2.06 
Elderly patients
Lung disease 4.76 
Receipt of mechanical ventilation 2.35 
Younger patients
Candidemia due to C. glabrata 6.32 
Lung disease 3.61 
Receipt of mechanical ventilation 2.62 
Receipt of total parenteral nutrition 2.53 
Receipt of dialysis 2.40 
Neutropenia 2.37 
OR, odds ratio; 95% CI, 95% conﬁdence interval.
a APACHE II score was excluded from the analysis because this variable was availabBrazil,21,22 and has been reported as 39% in Japan.23 In the present
study, elderly patients represented 46% of adult patients (>14
years old) and 31% of the 1485 adults and children in this cohort
(data not shown).
Cancer was the most frequent underlying disease in both
younger and older patients. However, while candidemia in
younger patients with cancer occurred more frequently in the
context of hematological malignancies and chemotherapy-in-
duced neutropenia, elderly cancer patients with candidemia were
more likely to have solid tumors. In addition, candidemia occurred
in the setting of complications of abdominal surgery rather thanients with candidemia
95% CI p-Value
1.97–9.59 <0.001
1.49–8.58 0.004
2.34–4.87 <0.001
1.81–3.78 <0.001
1.29–3.69 0.004
1.30–3.24 0.002
1.39–16.29 0.01
1.40–3.96 0.001
1.90–20.99 0.003
1.25–10.41 0.02
1.58–4.34 <0.001
1.41–4.54 0.002
1.19–4.84 0.01
1.19–4.73 0.01
le for only 220 patients.
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where patients were located when the candidemia developed:
younger patients in medical or hematology wards and elderly
patients in the ICU.
Elderly patients with candidemia had a higher prevalence of
diabetes mellitus and cardiac and pulmonary diseases, comorbid-
ities frequently found in this population. A higher prevalence in the
elderly of degenerative diseases, such as diabetes mellitus and
heart and lung diseases, has also been observed in other
studies.24,25 In contrast, young adults with candidemia had a
higher prevalence of liver disease, AIDS, and organ transplantation.
These data are consistent with the higher prevalence of these
conditions in individuals younger than 60 years of age. In this
context, the prevalence of candidemia in different underlying
diseases reﬂects the frequency distribution in the age groups.
Of note, despite the fact that elderly patients were sicker and
had multiple comorbidities at the time that candidemia was
diagnosed, the duration of hospitalization before developing
candidemia was signiﬁcantly shorter for young adults. This ﬁnding
may reﬂect the higher proportion of younger patients with
neutropenia and cancer chemotherapy. These patients usually
have repeated periods of hospitalization and are more likely to
have an episode of candidemia earlier in the hospitalization.
The species distribution in the present series is typical of the
epidemiology in the region, with a predominance of C. albicans, C.
tropicalis, and C. parapsilosis and low proportion of cases caused by
C. glabrata.26 Of note, we did not observe an increase in the
proportion of cases caused by C. glabrata in elderly patients, unlike
other reports in which this relationship has been observed.19,27,28
It is worth mentioning that the occurrence of C. glabrata in Brazil is
much lower than in the Northern Hemisphere.
In contrast, candidemia due to C. tropicalis was signiﬁcantly
more frequent in the elderly population. In Brazil, C. tropicalis is the
ﬁrst or second most frequent non-albicans species.26 As found in
the present study, an association between C. tropicalis candidemia
and elderly patients has also been reported in previous studies
conducted in Brazil, Saudi Arabia, Taiwan, and Singapore.29–32 In
the present study, we observed that the association between C.
tropicalis candidemia and elderly patients occurred in patients
with cancer but not in those without cancer. A better characteri-
zation of this epidemiology and the factors related to this high
proportion of C. tropicalis deserves further examination.
A major ﬁnding of the present study is the high mortality rate
for candidemia in patients 60 years of age. Not only did elderly
patients have a signiﬁcantly higher death rate, but the effect of age
group also remained signiﬁcant by multivariate analysis even after
controlling for APACHE II score. Most infections have poorer
outcomes in the elderly when compared with young adults.
Therefore, while it is reasonable to assume this difference in the
outcome just because of comorbidities and higher scores for
severity of illness, factors potentially prone to intervention should
be explored in future studies. Current guidelines for the manage-
ment of candidemia and invasive candidiasis recommend that a
fungicidal drug should be used as primary treatment if patients are
sick.30,32,33 Considering that in our study mortality was affected by
age group even after controlling for the APACHE II score and
comorbidities, should all patients 60 years receive a fungicidal
drug as primary treatment? Other factors that should be taken into
account in selecting a primary drug include the potential for
concomitant toxicity (especially for the kidneys) and drug
interactions, particularly with the growing incidence of poly-
pharmacy in elderly patients.34 In addition, some studies suggest
that comorbidities and functional status that are altered by age are
signiﬁcant risk factors for treatment failure.35,36
In the analysis of prognostic factors, excluding the APACHE II
score, signiﬁcant variables were lung disease and the receipt ofmechanical ventilation among elderly patients, and lung disease
and candidemia due to C. glabrata in younger patients. A more
precise interpretation of the association between lung disease and
higher mortality is hampered because our deﬁnition of lung
disease in this study was broad. The correlation between
mechanical ventilation and a higher risk of death is probably
secondary to the severity of the illness.
This study has some important limitations, the most signiﬁcant
being its retrospective nature. While all data had been collected
prospectively, some variables could not be explored because of
missing data. These included clinical manifestations of infection
(hypotension and hypo- and hyperthermia, among others), the
doses of corticosteroids, the APACHE II score (available for only 220
patients), and the timing of some interventions such as CVC
removal, which hampered an analysis of the effect of CVC removal
on the outcome.37
In conclusion, elderly patients account for a substantial
proportion of patients with candidemia and have higher mortality
compared with younger patients. Considering the high mortality
rate in this population, measures with a potential impact on
improving their outcome should be explored. These include an
early start to antifungal treatment (prophylactic, empiric, or
preemptive), as well as the use of fungicidal drugs with low
potential for toxicity and drug interactions as primary treatment.
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